Interobserver agreement on signs and symptoms of patients with acute febrile illness.

PURPOSE: To assess the interobserver agreement on clinical history and physical examination when using a semi-structured questionnaire to evaluate patients with an acute febrile illness (AFI). METHODS: A cross-sectional study was conducted with outpatients aged 12 years and over, presenting with an AFI defined as fever up to 7 days and no evident focus of infection. Clinical data were collected independently by two physicians using a semi-structured questionnaire. Interobserver agreement was estimated using kappa coefficients with a 95% confidence interval (CI). RESULTS: A total of 140 patients (age range 13-73 years; 56.4% females) were enrolled. All symptoms showed weighted kappa values significantly greater than 0.6, indicating an at least substantial agreement. As most physical signs were infrequent and of mild intensity, they were recoded and analyzed as absent/present. Of the signs with prevalence ≥15%, exanthema, pallor, lymph node enlargement, and eye congestion showed agreements significantly greater than 0.6, while kappa confidence limits for pharyngeal erythema and dehydration included values classified as regular. CONCLUSIONS: High agreement was observed for most of the clinical data assessed, and symptom grading was feasible. Some physical findings were rare and their inclusion in a structured form may not be justified in this setting. The questionnaire application showed good reliability for the most frequent signs and symptoms and may prove to be useful at gathering data for surveillance and research at sentinel sites.

Real-time digital heterodyne interferometer for high resolution plasma density measurements at ISTTOK.

With the implementation of alternating discharges (ac) at the ISTTOK tokamak, the typical duration of the discharges increased from 35 to 250 ms. This time increase created the need for a real-time electron density measurement in order to control the plasma fueling. The diagnostic chosen for the real-time calculation was the microwave interferometer. The ISTTOK microwave interferometer is a heterodyne system with quadrature detection and a probing frequency of 100 GHz (lambda(0)=3 mm). In this paper, a low-cost approach for real-time diagnostic using a digital signal programmable intelligent computer embedded system is presented, which allows the measurement of the phase with a 1% fringe accuracy in less than 6 micros. The system increases its accuracy by digitally correcting the offsets of the input signals and making use of a judicious lookup table optimized to improve the nonlinear behavior of the transfer curve. The electron density is determined at a rate of 82 kHz (limited by the analog to digital converter), and the data are transmitted for each millisecond although this last parameter could be much lower (around 12 micros--each value calculated is transmitted). In the future, this same system is expected to control plasma actuators, such as the piezoelectric valve of the hydrogen injection system responsible for the plasma fueling.

Real-time plasma control based on the ISTTOK tomography diagnostic.

The presently available processing power in generic processing units (GPUs) combined with state-of-the-art programmable logic devices benefits the implementation of complex, real-time driven, data processing algorithms for plasma diagnostics. A tomographic reconstruction diagnostic has been developed for the ISTTOK tokamak, based on three linear pinhole cameras each with ten lines of sight. The plasma emissivity in a poloidal cross section is computed locally on a submillisecond time scale, using a Fourier-Bessel algorithm, allowing the use of the output signals for active plasma position control. The data acquisition and reconstruction (DAR) system is based on ATCA technology and consists of one acquisition board with integrated field programmable gate array (FPGA) capabilities and a dual-core Pentium module running real-time application interface (RTAI) Linux. In this paper, the DAR real-time firmware/software implementation is presented, based on (i) front-end digital processing in the FPGA; (ii) a device driver specially developed for the board which enables streaming data acquisition to the host GPU; and (iii) a fast reconstruction algorithm running in Linux RTAI. This system behaves as a module of the central ISTTOK control and data acquisition system (FIRESIGNAL). Preliminary results of the above experimental setup are presented and a performance benchmarking against the magnetic coil diagnostic is shown.

[Applications of videolaparoscopic surgery in children] / Aplicações da cirurgia videolaparoscópica em crianças.

OBJECTIVES: To present the videolaparoscopies performed by the Childrens Surgery Service, and study the main indications for pediatric laparoscopic surgeries, considering advantages and disadvantages over conventional open procedures. METHODS: Retrospective analysis of 612 videolaparoscopies in children aged between 8 days and 17 years treated from November/95 to 2000. Basic principles of videolaparoscopy and the postoperative management of several pediatric diseases are described. The results, advantages, and complications were analyzed after a 5-year follow-up period. RESULTS: Laparoscopic surgery allowed for a wide series of abdominal procedures conventionally carried out through open surgery, mainly for the treatment of gastroesophageal reflux disease, inflammatory acute abdomen, adhesive intestinal obstruction, biliary lithiasis, tumors, cryptorchidism, ovarian diseases, splenectomies, aganglionosis, trauma and others. Morbidity was low (1%), and mortality due to laparoscopy was nonexistent. Conversion to laparotomy occurred in only 14 cases (2.3%), mainly because of trauma. The principal advantages included minimal surgical trauma, pain and reflex ileum, short hospital stay, almost no incisional hernias and better cosmetic scars. CONCLUSIONS: Videolaparoscopy seems to be a great advance in modern pediatric surgery, allowing safer and less invasive treatment of a wide series of abdominal diseases at all pediatric ages.

Interferon alfa recombinante no tratamento da hepatite C crônica / Recombinant alfa interferon in the treatment of chronic hepatitis C

Introduçao. A hepatite crônica pelo vírus C apresenta tendência evolutiva para cirrose hepática e hepatocarcinoma. Tratamento, com drogas antivirais, está indicado numa tentativa de modificar a evoluçao da doença. Objetivo. Avaliar a resposta de pacientes com hepatite crônica ou cirrose pós-hepatite C ao tratamento com interferon alfa recombinante e identificar os fatores associados com boa resposta terapêutica. Métodos. Foram estudados 38 pacientes com hepatite crônica ativa ou cirrose pelo vírus C, tratados com 2,5 a 3,0MU de interfon três vezes por semana, por períodos de 6 a 12 meses. Considerou-se resposta completa e duradoura quando a ALT e AST se mantinham normais por período de seis meses após o término do tratamento, e resposta completa com recidiva naqueles em que houve elevaçao das enzimas após a suspensao da droga. Resultados. Houve normalizaçao da ALT e AST em 17 dos 38 pacientes (44,7 por cento). Deste grupo, 9/17 tiveram resposta completa e duradoura, e em 8/17 houve aumento das enzimas após a interrupçao do tratamento. Houve uma tendência de melhor resposta ao interferon nos pacientes jovens e naqueles com hepatite crônica ativa (ao invéz da cirrose). Os efeitos colaterais mais frequentes foram febre (80 por cento), mialgia (60 por cento), astenia (50 por cento), cefaléia (40 por cento) e artralgia (36 por cento). Conclusoes. O tratamento com interfon alfa recombinante mostrou resposta satisfatória e duradoura em 23 por cento dos casos, com melhor resultado em pacientes jovens e sem cirrose associada.

[Recombinant interferon alfa in the treatment of chronic hepatitis C]. / Interferon alfa recombinante no tratamento da hepatite C crônica.

BACKGROUND: Chronic hepatitis C usually progresses to cirrhosis and hepatocarcinoma. Treatment with antiviral drugs is indicated attempting to modify the evolution of the disease. OBJECTIVE: To evaluate the treatment of chronic hepatitis C or post-hepatitis C cirrhosis with interferon-a-R (IFN) and to identify the factors associated with good therapeutic result. METHODS: Thirty eight patients with chronic hepatitis C or post-hepatitis C cirrhosis were treated with 2.5 or 3.0 MU of IFN three times a week for 6 to 12 months. We considered as a complete and sustained response when ALT and AST were normal for a 6 months period after finishing treatment. We considered complete response with relapse those in whom elevation of the enzymes was detected after drug suspension. RESULTS: There was normalization of ALT and AST in 17 out of 38 patients (44%). In this group, 9 out of 17 presented a complete and sustained response and in 8 out of 17 there was elevation of the enzymes after drug interruption. There was a trend of better response to interferon in patients below 40 years of age and in those with chronic active hepatitis. The most frequent side effects were fever (80%), myalgia (60%), asthenia (50%), headache (40%), and arthralgia (36%). CONCLUSION: Treatment with interferon showed a satisfactory and sustained response in 23% of the subjects, with better results in young patients and without cirrhosis.